Lincoln National vs. MetLife: The Valuation Gap Between a Shrinking Book and a Growing One

The question isn't which insurance stock is cheaper. The question is whether the cheapness is a discount or a diagnosis.

Lincoln National trades at 3.8 times trailing earnings. MetLife trades at 9.3 times forward earnings, with a $54 billion market cap to Lincoln National's $6.6 billion. On a spreadsheet, Lincoln National looks half-priced. On a business-quality basis, the gap tells a story about two companies on diverging paths.

Lincoln National: Cheap for a reason

Lincoln National's trailing P/E of 3.8 is not a market mistake. It's a reflection of a company whose core annuity book is slowly running off, whose Q1 2026 total sales of $3.9 billion saw fixed annuity sales of $716 million below the prior year, and whose 2025 tariff shock wiped out 26% of the stock. The Q1 2026 EPS beat - $1.66 versus analyst expectations - looks good on its own. The context matters more: it came on a smaller, lower-growth base, not a reaccelerating one.

Book value per share sits around $48 to $78 depending on which accounting measure you use - that $78 figure includes unrealized gains and losses in accumulated other comprehensive income, which can reverse. At $35 a share, Lincoln National trades at roughly 45% of that higher book measure. That kind of deep discount to book usually signals one of two things: the market expects book to shrink faster than current run-off suggests, or the asset base carries concentration risk. In Lincoln National's case, it's both.

The dividend yield is real and attractive: 5.1%, one of the highest in the insurance sector. For the income sleeve, that matters. But the yield is high partly because the price has been pushed down by annuity runoff dynamics and equity-market sensitivity. A 5% yield on a shrinking base is not the same as a 5% yield on a compounding one. The portfolio role here is income with tolerance for principal risk - not growth.

Analyst consensus is Hold, with an average 12-month price target around $43. Morgan Stanley's May 2026 target was $40. That $43 figure implies roughly 23% upside from current levels - not a ringing endorsement. Analysts see the yield, see the cheapness, but see the trajectory too.

MetLife: Expensive for a reason

MetLife's $84 price, forward P/E of 9.3, and 2.8% dividend yield don't read like a bargain. Read them alongside Q1 2026 results and the comparison changes. Asia adjusted earnings jumped 31% to $487 million. EMEA (Europe, Middle East, Africa) adjusted earnings were up 33% to $110 million. Latin America was up 5% to $229 million. Management described the mix between yen and dollar products as close to 50/50, meaning currency volatility is partially hedged by the business structure itself.

This is what the higher multiple is buying: geographic diversification across three international growth regions, not a concentrated U.S. annuity portfolio in structural decline. MetLife also increased its quarterly dividend 4.4% to $0.5925 per share in April 2026, with a three-year average dividend growth rate of 4.32%. The 2.8% yield is lower than Lincoln National's, but it's growing on a stable base rather than compensating for a falling one.

Analyst consensus is Buy across 13 analysts, with an average target of $95 - roughly 13% above the current price. Morgan Stanley, Jefferies, and JPMorgan all carry Overweight ratings. The market isn't pricing MetLife as a deep-value name. It's pricing it as a mid-cycle growth story in a sector most people treat as defensive income.

The comparison, straight

The spreadsheet says Lincoln National is the better value. The business trajectory says something different. Lincoln National's low multiples are a function of annuity book run-off and U.S.-only concentration - structural headwinds, not a temporary cycle. MetLife's premium reflects international growth, diversification, and an analyst street that expects that momentum to continue.

Neither stock is wrong. They're just different sleeves. Lincoln National belongs in a high-yield income allocation where you accept that the underlying book may not compound. MetLife belongs in a quality-growth sleeve where you pay a moderate premium for geographic diversification and earnings acceleration.

If the macro environment stays uncertain - and the tariff volatility of 2025 suggests it will - the barbell approach works better than choosing one: use Lincoln National for yield and MetLife for growth. But don't confuse the P/E gap with an arbitrage. The market usually gets the direction right even when the magnitude is debatable.

What would change the call? If Lincoln National's annuity sales stabilize or book value stops declining, the 3.8 P/E becomes a real mispricing worth attacking. If MetLife's international growth stalls and the Asia/EMEA momentum reverses, the 9.3 forward multiple starts looking expensive for a name that still carries legacy U.S. exposure. Until then, the factor stack on each name looks like what it is: discount on the left, premium on the right. Both earned.